Document Type : Research articles
Authors
1 Alanya Alaaddin Keykubat University, Faculty of Medicine, Department of Medical Pathology, Antalya, Turkey
2 Alanya Alaaddin Keykubat University, Faculty of Medicine, Department of Otolarngology, Antalya,Turkey
Abstract
Background: Programmed Death-Ligand 1 (PD-L1) is a cell membrane protein found on the surface of cancer cells, immune system cells in the tumor microenvironment, and various healthy tissues. Moreover, it plays a key role in suppressing the immune system.
Objectives: We aim to explain the presence of PD-L1 in Head-Neck Squamosus Cell Carcinomas (HNSCC) and premalign lesions by immunohistochemical method.
Methods: Our retrospective study included 22 patients with HNSCC (15(68.1%) Oral cavity and 7(31.9%) Oropharynx), 20 patients with oral lichen planus, and 14 patients with normal oral cavity mucosa. In the evaluation of PD-L1 antibodies applied immunohistochemically in patients with HNSCC, the percentage of tumor cells showing membranous staining with PD-L1 antibodies was calculated.
Results: The mean age of HNSCC patients participating in the study was 52.24 ± 11.7 years, the mean age of oral lichen planus patients was 34.10 ± 9.8 years, and the control patients' mean age was 31.42 ± 10.6 years. The rate of PD-L1 staining of tumor cells of HNSCC patients was significantly higher than the control group (P=0.001).
Conclusion: The importance of PD-L1 expression in HNSCC and precancerous lesions of the oral cavity is remarkable, and the values may be related to the pathophysiology of these diseases.
Keywords
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
- Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the international head and neck cancer epidemiology consortium. Am J Epidemiol. 2013;178(5):679–90. doi: 10.1093/aje/kwt029. [PubMed: 23817919].
- Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–41. doi: 10.1158/0008-5472.can-12-2384. [PubMed: 23288508].
- Liao W, Zheng H, Wu S, Zhang Y, Wang W, Zhang Z, et al. The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from Nephritis. Am J Nephrol. 2017;46(5):371-9. doi: 10.1159/000480641. [PubMed: 29069649].
- Canavan M, Floudas A, Veale DJ, Fearon U. The PD-1:PD-L1 axis in ınflammatory arthritis. BMC Rheumatol. 2021;5(1):1. doi: 10.1186/s41927-020-00171-2. [PubMed: 33423684].
- Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, et al. HLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000157. doi: 10.1136/jitc-2019-000157. [PubMed: 31959726].
- Ettrich TJ, Seufferlein T. Systemic therapy for metastatic Pancreatic Cancer. Curr Treat Options Oncol. 2021;22(11):106. doi: 10.1007/s11864-021-00895-4. [PubMed: 34665339].
- Gil Del Alcazar CR, Trinh A, Alečković M, Rojas Jimenez E, Harper NW, Oliphant MU, et al. Insights into ımmune escape during tumor evolution and response to ımmunotherapy using a rat model of Breast Cancer. Cancer Immunol Res. 2022;10(6):680-97. doi: 10.1158/2326-6066.CIR-21-0804. [PubMed: 35446942].
- Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. doi: 10.3390/cancers12030738. [PubMed: 32245016].
- Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(5):184–6. doi: 10.1093/annonc/mdq185. [PubMed: 20555077].
- Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873-98. doi: 10.6004/jnccn.2020.0031. [PubMed: 32634781].
- Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605-11. doi: 10.1093/annonc/mdx178. [PubMed: 28419181].
- Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Dorpe JV, Ferdinande L, et al. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncol. 2017;70:34-42. doi: 10.1016/j.oraloncology.2017.05.002. [PubMed: 28622889].
- Martinez Marti A, Martinez P, Navarro A, Cedres S, Murtra-Garrell N, Salva F, et al. Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung. J Clin Oncol. 2014;15:7569. doi: 10.1200/jco.2014.32.15_suppl.7569.
- Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. doi: 10.1056/NEJMoa1602252. [PubMed: 27718784].
- Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48(2):527–36. doi: 10.4143/crt.2015.249. [PubMed: 26511814].
- Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, et al. Molecular profiling of head and neck squamous cell carcinoma. Head Neck. 2016;38(1):1625–38. doi: 10.1002/ hed.24290. [PubMed: 26614708].
- Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol. 2016;101:75-85. doi: 10.1016/j.critrevonc.2016.03.007. [PubMed: 26969107].
- Cho YA, Yoon H Y, Lee J, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncology. 2011;47(12):
- -53. doi: 10.1016/j.oraloncology.2011.08.007. [PubMed: 21911310].
- Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, et al. Programmed cell death-ligand 1 expression in
- oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology. 2016;48(6):574–80. doi: 10.1016/j.pathol.2016.07.003. [PubMed: 27590194].
- Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K. Tumorinfiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):744–52. Doi: 10.1016/j.tripleo.2009.12.015. [PubMed: 20303300].
- Qiao B, Huang J, Mei Z, Lam AK, Zhao J, Ying L. Analysis of ımmune microenvironment by multiplex ımmunohistochemistry staining in different oral diseases and oral squamous cell carcinoma.
- Front Oncol. 2020;10:555757. doi: 10.3389/fonc.2020.555757. [PubMed: 33364188].
- Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. [PubMed: 24714771].
- Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, Amaya P, Wu Y, Park KJ, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget. 2015;6(25):20902-20. doi: 10.18632/oncotarget.3939. [PubMed: 26041877].
- Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. [PubMed: 24127443].
- Chen XJ, Tan YQ, Zhang N, He MJ, Zhou G. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. Pathol Res Pract. 2019;215(6):152418. doi: 10.1016/j.prp.2019.04.010. [PubMed: 31027907].
- Saraggi D, Galuppini F, Remo A, Urso ED, Bacchin D, Salmaso R, et al. PD‐L1 overexpression in ampulla of Vater carcinoma and its pre‐invasive lesions. Histopathology. 2017;71(3):470-4. doi: 10.1111/his.13254. [PubMed: 28502094].
- Belkhir R, Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747-50. Doi: 10.1136/annrheumdis-2017-211216. [PubMed: 28600350].
- Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki A, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60(1):207-18. doi: 10.1002/art.24227. [PubMed: 19116915].
- Ghanizada M, Jakobsen KK, Gronhoj C, Buchwald VC. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. Oral Oncol. 2019;90:67-73. doi: 10.1016/j.oraloncology.2019.01.018. [PubMed: 30846179].